Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    Open Studies | "Raynaud Disease"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Raynaud Disease" (7 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
Condition: Raynaud's Disease
Interventions: Other: placebo;   Dietary Supplement: diosmiplex
2 Recruiting PORH and Response to Cold in Raynaud's Phenomenon.
Conditions: Raynaud Disease;   Hyperemia;   Cold
Interventions: Procedure: post-occlusive hyperemia;   Procedure: cooling box;   Drug: L-NMMA and Fluconazole dermic injection
3 Not yet recruiting Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
Conditions: Raynaud Disease;   Systemic Sclerosis;   Digital Ulcer
Interventions: Drug: Calcium Channel Blockers;   Drug: Phosphodiesterase Inhibitors;   Drug: Endothelin receptor blocker;   Drug: Prostanoids;   Drug: Other vasodilator
4 Recruiting Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: oral treprostinil;   Drug: Placebo
5 Not yet recruiting Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Conditions: Primary Raynaud's Phenomenon (PR);   Genetic Mutations Causing PR;   Study of Patients and Their Relatives (With or Without Primary PR)
Intervention: Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon
6 Not yet recruiting Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Condition: Raynaud's Phenomenon Secondary to Connective Tissue Disease
Interventions: Drug: Vascana (0.9% nitroglycerin cream);   Drug: Vehicle (placebo)
7 Not yet recruiting Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Condition: Secondary Raynaud's Phenomenon
Intervention: Drug: Neovasculgen

Study has passed its completion date and status has not been verified in more than two years.